Bone Metastases COE

The REASSURE Trial: Long-Term Safety of Radium-223 in Advanced Prostate Cancer - Oliver Sartor

Details
Oliver Sartor discusses the REASSURE study with Alicia Morgans. The study investigates the long-term side effects of radium, the first approved alpha emitter, on prostate cancer patients. With over 1,400 patients involved, the study monitors side effects such as fractures, bone marrow failure, and secondary malignancies over the course of years. Interestingly, the study found fewer side effects th...

Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan

Details
Alicia Morgans, Neeraj Agarwal, and Ben Maughan discuss the publication of a study on a combination of enzalutamide and radium-223 that evaluated the utility of bone metabolic markers (BMM) as surrogate markers of response to radium-223 in mCRPC. Biographies: Neeraj Agarwal, MD, Clinical Research Innovation, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, UT Benjamin L. Maug...

Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi

Details
As part of this patient-centered video series of lectures on prostate cancer diagnosis and treatment, Dr Sethi presents the timing for radium-223 treatment in mCRPC. She details who qualifies as a candidate for radium 223 therapy, how it is given, the limited side effects of this treatment, that PSA is not a biomarker for treatment success and other treatment management considerations. Biography:...

The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

Details
In this conversation with Alicia Morgans, Silke Gillessen highlights the bone health analysis evaluating the combination of enzalutamide and radium or enzalutamide alone might affect bone health and fracture rate within patients with metastatic castration-resistant prostate cancer. At the 2021 ASCO meeting, Dr. Gillessen presented an updated safety analysis from the EORTC 1333 / PEACE III trial of...